Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | terminated | Phase 1 | 64 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04659369 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC | terminated | Phase 1 | 21 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | terminated | Phase 1 / Phase 2 | 1 | Ivan LitvinovOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | terminated | Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 2 | SecuraBioINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 15 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | terminated | Phase 1 / Phase 2 | 25 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03906526 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | terminated | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 12 | NYU Langone HealthOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | terminated | Phase 1 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02429089 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck(CETLEE011) | terminated | Phase 1 | 21 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | terminated | Phase 1 | 18 | CelgeneINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Nov 4, 2024source: clinicaltrials